Clifford Charles Sheckter

Clifford Charles Sheckter

Auto-generated profile, based on publicly available information

Clifford Charles Sheckter

Department of Surgery, Stanford University School of Medicine , Stanford, CA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Burns
Verified
Journal Article
Closed access
SHSamantha Huang
Samantha Huang
JDJustin Dang
Justin Dang
CSClifford C. Sheckter
Clifford C. Sheckter
HYHaig A. Yenikomshian
Haig A. Yenikomshian
JGJustin Gillenwater
Justin Gillenwater

1 February 2023 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
DRDanielle H. Rochlin
Danielle H. Rochlin
NRNada M. Rizk
Nada M. Rizk
EMEvan Matros
Evan Matros
TWTodd H. Wagner
Todd H. Wagner
CSClifford C. Sheckter
Clifford C. Sheckter
Importance: Breast reconstruction is costly, and negotiated commercial rates have been hidden from public view. The Hospital Price Transparency Rule was enacted in 2021 to facilitate market competition and lower health care costs. Breast reconstruction pricing should be analyzed to evaluate for market effectiveness and opportunities to lower the cost of health care.Objective: To evaluate the extent of commercial price variation for breast reconstruction. The secondary objective was to characterize the price of breast reconstruction in relation to market concentration and payer mix.Design, Setting, and Participants: This was a cross-sectional study conducted from January to April 2022 using 2021 pricing data made available after the Hospital Price Transparency Rule. National data were obtained from Turquoise Health, a data service platform that aggregates price disclosures from hospital websites. Participants were included from all hospitals with disclosed pricing data for breast reconstructive procedures, identified by Current Procedural Terminology (CPT) code.Main Outcomes and Measures: Price variation was measured via within- and across-hospital ratios. A mixed-effects linear model evaluated commercial rates relative to governmental rates and the Herfindahl-Hirschman Index (health care market concentration) at the facility level. Linear regression was used to evaluate commercial rates as a function of facility characteristics.Results: A total of 69 834 unique commercial rates were extracted from 978 facilities across 335 metropolitan areas. Commercial rates increased as health care markets became less competitive (coefficient, $4037.52; 95% CI, $700.12 to $7374.92; P = .02; for Herfindahl-Hirschman Index [HHI] 1501-2500, coefficient $3290.21; 95% CI, $878.08 to $5702.34; P = .01; both compared with HHI ≤1500). Commercial rates demonstrated economically insignificant associations with Medicare and Medicaid rates (Medicare coefficient, −$0.05; 95% CI, −$0.14 to $0.03; P = .23; Medicaid coefficient, $0.14; 95% CI, $0.07 to $0.22; P < .001). Safety-net and nonprofit hospitals reported lower commercial rates (coefficient, −$3269.58; 95% CI, −$3815.42 to −$2723.74; P < .001 and coefficient, −$1892.79; −$2519.61 to −$1265.97; P < .001, respectively). Extra-large hospitals (400+ beds) reported higher commercial rates compared with their smaller counterparts (coefficient, $1036.07; 95% CI, $198.29 to $1873.85, P = .02).Conclusions and Relevance: Study results suggest that commercial rates for breast reconstruction demonstrated large nationwide variation. Higher commercial rates were associated with less competitive markets and facilities that were large, for-profit, and nonsafety net. Privately insured patients with breast cancer may experience higher premiums and deductibles as US hospital market consolidation and for-profit hospitals continue to grow. Transparency policies should be continued along with actions that facilitate greater health care market competition. There was no evidence that facilities increase commercial rates in response to lower governmental rates.

13 August 2018 in Burns
Verified
Journal Article
Closed access
PDF file
CSClifford C. Sheckter
Clifford C. Sheckter
KHKay S. Hung
Kay S. Hung
DRDanielle Rochlin
Danielle Rochlin
ZMZeshaan Maan
Zeshaan Maan
YKYvonne Karanas
Yvonne Karanas
CCCatherine Curtin
Catherine Curtin

1 February 2019 in Burns
Verified
Journal Article
Closed access
CSClifford C. Sheckter
Clifford C. Sheckter
HKHarriet Kiwanuka
Harriet Kiwanuka
ZMZeshaan Maan
Zeshaan Maan
EPElizabeth Pirrotta
Elizabeth Pirrotta
CCCatherine Curtin
Catherine Curtin
NWNancy E. Wang
Nancy E. Wang

1 March 2018 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
CSClifford C. Sheckter
Clifford C. Sheckter
EMEvan Matros
Evan Matros
AMArash Momeni
Arash Momeni

1 February 2020 in Burns
Verified
Journal Article
Closed access
CSClifford C. Sheckter
Clifford C. Sheckter
CPChristopher Pham
Christopher Pham
DRDanielle Rochlin
Danielle Rochlin
ZMZeshaan N. Maan
Zeshaan N. Maan
YKYvonne Karanas
Yvonne Karanas
CCCatherine Curtin
Catherine Curtin